免疫检查点抑制剂与免疫相关肾脏不良事件
本文综述免疫检查点抑制剂(ICI)相关肾毒性的发生率、危险因素及管理策略,重点讨论ICI相关急性肾损伤(AKI)后再次挑战的「是否、何时、如何」问题,以及移植人群使用ICI时急性排斥的风险。
要点
- ICI相关肾毒性日益被认识,临床需掌握其管理方法。
- ICI相关AKI后是否再次挑战ICI尚不明确,是临床难题。
- 移植患者使用ICI可能促进急性排斥,需权衡风险。
核心结论
- ICI相关肾毒性需合理管理以改善癌症患者结局,但ICI再挑战策略尚不明确。
研究设计与样本
- 综述,总结ICI相关肾毒性的发生率、危险因素及管理信息。
主要发现
- ICI相关肾毒性日益被认识,近期研究描述了其发生率与潜在危险因素。
- ICI相关AKI后再次挑战ICI的「是否、何时、如何」问题对临床医生构成难题。
- 移植人群使用ICI治疗癌症时存在促进急性排斥的担忧。
临床怎么用
- 临床医生应掌握ICI相关肾毒性的管理方法以优化癌症患者结局。
- 对ICI相关AKI后是否再挑战ICI需个体化决策,目前证据不明确。
- 移植患者使用ICI时应警惕急性排斥风险。
局限性
- ICI相关AKI后再挑战ICI的策略尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Renal toxicities have been increasingly recognized as complications of the immune checkpoint inhibitors (ICIs). Recent studies have outlined the incidence and potential risk factors for nephrotoxicity. For clinicians, the key question is how to manage patients who develop these adverse renal effects. This is of paramount importance to providers as ICI use for cancer therapy becomes more widespread and nephrotoxicity increasingly develops. As clinicians encounter ICI-associated nephrotoxicity, an appropriate approach to management is required to facilitate the best outcomes in patients with cancer. Importantly, ICI rechallenge in patients who developed ICI-related acute kidney injury (AKI) is unclear and represents a conundrum for providers. Clinicians struggle with the "if, when, and how to" questions related to ICI rechallenge in this subset of patients. In addition, ICI use in the transplant population raises concerns for promoting acute rejection when treating cancer in these patients. We herein review current information on these various topics.
引用
- Herrmann SM, Perazella MA. Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events. Kidney Int Rep. 2020. PMID: 32775813. doi:10.1016/j.ekir.2020.04.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。